As the United States market navigates a complex landscape marked by trade policy uncertainties and fluctuating economic indicators, major indices like the Dow Jones Industrial Average and S&P 500 remain near record highs despite recent tariff threats. In this environment, high-growth tech stocks become particularly intriguing as investors seek opportunities that demonstrate resilience and potential for expansion amidst these broader market dynamics.
|
Name |
Revenue Growth |
Earnings Growth |
Growth Rating |
|---|---|---|---|
|
Super Micro Computer |
25.14% |
38.20% |
★★★★★★ |
|
Circle Internet Group |
30.80% |
60.64% |
★★★★★★ |
|
Ardelyx |
21.16% |
61.58% |
★★★★★★ |
|
Mereo BioPharma Group |
51.11% |
57.42% |
★★★★★★ |
|
TG Therapeutics |
26.05% |
39.12% |
★★★★★★ |
|
AVITA Medical |
27.42% |
61.04% |
★★★★★★ |
|
Alnylam Pharmaceuticals |
23.85% |
59.41% |
★★★★★★ |
|
Alkami Technology |
20.53% |
76.67% |
★★★★★★ |
|
Ascendis Pharma |
34.89% |
59.89% |
★★★★★★ |
|
Lumentum Holdings |
23.48% |
103.97% |
★★★★★★ |
Click here to see the full list of 227 stocks from our US High Growth Tech and AI Stocks screener.
Underneath we present a selection of stocks filtered out by our screen.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: MannKind Corporation is a biopharmaceutical company that develops and commercializes therapeutic products for endocrine and orphan lung diseases in the United States, with a market cap of $1.15 billion.
Operations: Focusing on the U.S. market, MannKind Corporation generates revenue primarily from its pharmaceuticals segment, which accounts for $297.60 million.
MannKind Corporation, despite recent challenges such as being dropped from several Russell indexes, demonstrates robust growth in its niche biotech sector. With an impressive 254.8% surge in earnings over the past year outpacing the industry's 21.7%, MannKind is making significant strides, especially noted during their presentation at the American Diabetes Association's Scientific Sessions. They showcased advancements in inhaled insulin treatments, highlighting their commitment to innovation despite a revenue growth forecast of 12.4% per year—slightly below high-growth benchmarks but still ahead of the US market average of 8.8%. This performance underpins a strategic focus that could reshape diabetic treatment paradigms and foster sustained growth amidst evolving market dynamics.
Simply Wall St Growth Rating: ★★★★★★
Overview: Blueprint Medicines Corporation is a precision therapy company focused on developing medicines for genomically defined cancers and blood disorders, with a market cap of $8.37 billion.
